PROFILPELAJAR.COM

Elisrasib

Elisrasib
Clinical data
Other namesD3S-001
Identifiers
  • [(2S)-4-[(7S)-7-[3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl]-2-{[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC32H35F6N7O3
Molar mass679.668 g·mol−1
3D model (JSmol)
  • CC1=CC(=C(C(=C1C(F)(F)F)[C@@H]2CC3=C(CO2)C(=NC(=N3)OC[C@@]45CCCN4C[C@@H](C5)F)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F)F)N
  • InChI=InChI=1S/C32H35F6N7O3/c1-17-10-22(40)27(35)25(26(17)32(36,37)38)24-11-23-21(15-47-24)28(43-8-9-45(29(46)18(2)33)20(14-43)4-6-39)42-30(41-23)48-16-31-5-3-7-44(31)13-19(34)12-31/h10,19-20,24H,2-5,7-9,11-16,40H2,1H3/t19-,20+,24+,31+/m1/s1
  • Key:JOLORSRKBHXPFT-PNGHJTAWSA-N

Elisrasib is an investigational new drug that is being developed by D3 Bio for the treatment of solid tumors. It is a G12C mutant selective KRAS inhibitor.[1][2][3][4]

References

  1. ^ "Elisrasib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. ^ Zhang J, Lim SM, Yu MR, Chen C, Wang J, Wang W, et al. (September 2024). "D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities". Cancer Discovery. 14 (9): 1675–1698. doi:10.1158/2159-8290.CD-24-0006. PMC 11372373. PMID 38717075.
  3. ^ Killock D (July 2025). "Next-generation KRAS-G12C inhibitor D3S-001 shows promise". Nature Reviews. Clinical Oncology. 22 (7): 459. doi:10.1038/s41571-025-01028-8. PMID 40346420.
  4. ^ "Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC". Cancer Discovery. 16 (6): OF1. June 2026. doi:10.1158/2159-8290.CD-NW2026-0041. PMID 42010749.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.